Clinical Lymphoma, Myeloma & Leukemia最新文献

{"title":"Feasibility of Bruton's Tyrosine Kinase Inhibitor Discontinuation in Chronic Lymphocytic Leukemia: The Patient Perspective.","authors":"Deborah M Stephens, Chris Stewart, Liza Avruch, Catherine C Coombs, Alexey Danilov, Brian Hill, Mazyar Shadman, Alina Gerrie, Christopher E Jensen, Marc Hoffmann, Allison Winter, Daniel A Ermann, Paul M Barr, Susan O'Brien, Brian Koffman, John C Byrd","doi":"10.1016/j.clml.2025.05.011","DOIUrl":"https://doi.org/10.1016/j.clml.2025.05.011","url":null,"abstract":"<p><strong>Background: </strong>Bruton's tyrosine kinase inhibitors (BTKi) have prolonged survival in chronic lymphocytic leukemia (CLL), however continuous administration increases toxicity. Little is known about clinical outcomes of patients who discontinue BTKi for reasons other than CLL progression. We aimed to report these outcomes.</p><p><strong>Patients/methods: </strong>With the CLL Society, we solicited volunteers with CLL who self-reported BTKi discontinuation for reasons other than CLL progression to participate in a web-based survey.</p><p><strong>Results: </strong>In 170 patients, BTKi was discontinued for toxicity, because CLL was in remission, or personal choice in 62%, 14% and 8%, respectively. When asked how they felt about stopping the BTKi, most were relieved that they may eliminate toxicity (45%), could focus less on CLL (11%), and would not have to pay for the medicine (7%), while 29% experienced anxiety. A statistically significant increase in perceived quality of life (QOL) was observed from prior- versus post-BTKi discontinuation. Of patients who reported that they experienced clinical CLL progression (n = 80), 46% reported that these events did not happen for ≥ 1 year after BTKi discontinuation. Those that were on a BTKi for ≥ 2 years before discontinuation had more time without CLL relapse.</p><p><strong>Conclusions: </strong>These data provide a unique report of patient experiences. The data suggest that BTKi may be feasible and result in a period of treatment-free remission. The data also indicate that patients are generally relieved when they anticipate BTKi discontinuation and observe significant QOL improvements after BTKi discontinuation. As such, these data should prompt prospective study of time-limited BTKi therapy for CLL.</p>","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-05-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144246758","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Incidence and Risk Factors for Pneumonitis Associated With Checkpoint Inhibitors in Relapsed or Refractory Lymphoma.","authors":"Felipe Soto, Ugochi Ebinama, William P Brasher, William C Harding, Alberto Goizueta, Jeremy R Walder, Alexandra Ewing, Vickie R Shannon, Saadia A Faiz, Mehmet Altan, Girish Shroff, Lei Feng, Sattva Neelapu, Sairah Ahmed, Loretta J Nastoupil, Ajay Sheshadri","doi":"10.1016/j.clml.2025.05.008","DOIUrl":"https://doi.org/10.1016/j.clml.2025.05.008","url":null,"abstract":"<p><strong>Introduction: </strong>Immune checkpoint inhibitors (ICI) have revolutionized relapsed/refractory lymphoma treatment but can cause severe immune-related adverse events (irAEs), including pneumonitis. The incidence and risk factors for ICI-pneumonitis in real-world lymphoma cohorts remain unreported.</p><p><strong>Methods: </strong>We retrospectively reviewed 302 lymphoma patients treated with PD-1 inhibitors at MD Anderson (2015-2022). A multidisciplinary team adjudicated grade ≥ 2 pneumonitis (CTCAEv5). We analyzed demographic, clinical, and treatment data. Cox proportional hazards models assessed univariate and multivariate associations (P < .1 for inclusion).</p><p><strong>Results: </strong>Pneumonitis occurred in 16/302 patients (5%). Univariate analysis identified risk factors: CTLA-4 combination (13.5, 95% CI, 1.7-104.7, P = .01), pre-ICI hypoxemia (HR = 9.2, 95% CI, 2.9-29, P < .001), pre-ICI dyspnea (HR = 3.1, 95% CI, 1.1-8.6, P = .02), CD25-ADC (HR = 4.6, 95% CI, 1.04-21.03, P = .04), and IAP antagonists (HR = 9.2, 95% CI, 1.18-71.2, P = .03). In multivariate analysis, independent risk factors included pre-ICI dyspnea (HR = 4.6, 95% CI, 1.5-14, P = .007), CTLA-4 combination (HR = 24, 95% CI, 2.9-204, P = .003), IAP antagonists (HR = 23.8, 95% CI, 2.6-218, P = .005), and PI3K inhibitors (HR = 14.6, 95% CI, 1.7-123, P = .01). Pneumonitis was not associated with mortality (HR = 0.7, 95% CI, 0.2-2.5, P = .69).</p><p><strong>Discussion: </strong>ICI-pneumonitis incidence was 5%, typically low-grade. CD25-ADC's link to pneumonitis may stem from regulatory T cell depletion. IAP antagonists, which enhance Th1/TNF-α responses, may result in cytotoxic pulmonary injury. PI3K inhibitors, which have been independently associated with pneumonitis, may synergize with ICIs to potentiate risk for pneumonitis.</p>","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-05-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144293376","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"SOHO State of the Art Updates and Next Questions | The Evolving Landscape of Prognostic Models in Chronic Lymphocytic Leukemia.","authors":"Stefano Molica, Ahmad Ibrahim, David Allsup","doi":"10.1016/j.clml.2025.05.010","DOIUrl":"https://doi.org/10.1016/j.clml.2025.05.010","url":null,"abstract":"<p><p>The advent of targeted therapies has profoundly altered the prognostic landscape of chronic lymphocytic leukemia (CLL), demanding a reassessment of established predictive models. Initial frameworks, such as the CLL International Prognostic Index (CLL-IPI), primarily relied on clinical and genetic parameters. However, the growing clinical utility of targeted agents highlights the ongoing need to refine these prognostic tools. Although the CLL-IPI remains a valuable metric for progression-free survival (PFS), its capacity to accurately predict overall survival (OS) has been attenuated by the evolution of therapeutic approaches. Novel prognostic models hold promise by leveraging advanced technologies, sophisticated statistical methods, and computational analytics to improve risk stratification. These innovations address the inherent limitations of conventional models, enabling more precise and individualized prognostic assessments. To maintain clinical utility, however, these models must continuously adapt alongside the rapidly advancing therapeutic landscape of CLL. Optimizing patient outcomes requires a fundamental paradigm shift that integrates a broader and more dynamic array of patient-specific data into prognostic evaluations.</p>","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144246760","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparative Efficacy and Safety of Daratumumab-Integrated Quadruple Therapy Versus Triple Therapy in Transplant-Eligible Newly Diagnosed Multiple Myeloma: A Systematic Review and Meta-Analysis.","authors":"Kleuber Arias Meireles Martins, Leonardo Januário Campos Cardoso, Filipe Melo Ribeiro, André Luís Pereira, Pedro Henrique Gibram Gontijo, João Pedro Oliveira, Pedro Luiz Lage Bodour Danielian, André Dias Américo, Phillip Scheinberg","doi":"10.1016/j.clml.2025.05.007","DOIUrl":"https://doi.org/10.1016/j.clml.2025.05.007","url":null,"abstract":"<p><strong>Background: </strong>The standard treatment for newly diagnosed, transplant-eligible multiple myeloma (NDMM) patients typically involves triplet therapy (TT) with bortezomib, lenalidomide or thalidomide, and dexamethasone, followed by autologous stem-cell transplantation. Adding daratumumab, a CD38-targeting monoclonal antibody, to TT has shown promise, though available evidence remains limited. This study systematically reviews and analyzes the impact of adding daratumumab to TT in these patients.</p><p><strong>Methods: </strong>PubMed, Embase, Web of Science, and Cochrane databases were searched for articles comparing the daratumumab integrated QT and standard TT for NDMM. Endpoints included overall response rate (ORR), complete response (CR) or better, disease progression or death, progression-free survival (PFS), overall survival (OS), minimal residual disease (MRD) negativity rate, and adverse events (AEs). Pooled relative risk (RR), and hazard ratios (HR) with 95% CI were calculated using a random-effects model. Heterogeneity was assessed using I² statistics.</p><p><strong>Results: </strong>Five studies involving 3407 patients (1,371 received QT) were included. Disease progression or death was significantly lower in the quadruplet group. Patients receiving QT presented significantly higher PFS and OS, along with higher rates of ORR, and MRD negativity rate. Additionally, the QT group showed a trend towards an increase in CR or better. The risk for both hematological and non-hematological AEs was higher in the QT group.</p><p><strong>Conclusion: </strong>The findings suggest that incorporating daratumumab into standard TT for treating transplant-eligible NDMM patients is associated with higher response rates and reduced disease progression and mortality. However, it is important to note that this regimen also comes with a higher incidence of AEs.</p>","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144233377","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Blood-Based Measurable Residual Disease by Clonotypic Mass Spectrometry is Prognostic in Patients With Multiple Myeloma Undergoing Autologous Hematopoietic Cell Transplant.","authors":"Michael J Slade, Julie Fortier, Abir Khaled, Mark Fiala, Zac McDonald, Mark A Zaydman, Fei Wan, Mark A Schroeder, Keith Stockerl-Goldstein, Liqiang Yang, Ravi Vij","doi":"10.1016/j.clml.2025.04.017","DOIUrl":"https://doi.org/10.1016/j.clml.2025.04.017","url":null,"abstract":"<p><strong>Background: </strong>While marrow-based measurable residual disease (MRD) testing for multiple myeloma (MM) is highly associated with outcomes, it is challenging to implement for serial monitoring. Consequently, blood-based MRD testing is desirable.</p><p><strong>Patients and methods: </strong>In this study, we investigated the use of clonotypic mass spectrometry (CT-MS) for blood-based monitoring of M-protein in patients undergoing autologous hematopoietic cell transplant (AHCT). We performed a pilot analysis to assess assay performance, then restricted our analysis of CT-MS as a blood-based MRD assay to patients with 1) banked baseline samples pre-AHCT, 2) no M-protein on serum protein electrophoresis at day +100 post-AHCT and 3) available samples at day +100.</p><p><strong>Results: </strong>One hundred and eleven patients with analyzed, with 94 patients included in the MRD analysis. We derived a proposed threshold for MRD via the minimal P-value approach using two different methods. We found that CT-MS MRD-positivity at day + 100 post-AHCT was significantly associated with worse progression-free survival (PFS) (P < .0001, median PFS 2.5 vs. 8.4 years), with a HR of 3.74 (P = .0002). This association was stable on multi-variable analysis (MVA) adjusting for known risk factors (aHR: 3.68, P = .003). CT-MS MRD-positivity was also associated with significantly worse overall survival (median: 4.95 years vs. not reached, P = .001, HR: 3.95), stable on MVA (aHR: 3.25, P = .01).</p><p><strong>Conclusion: </strong>Our study suggests CT-MS may be a useful tool for blood-based MRD in multiple myeloma (MM).</p>","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144265466","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Guidelines on Management of Multiple Myeloma in the Relapsed/Refractory Setting: The Saudi Myeloma Working Group Guideline.","authors":"Ayman Alhejazi, Ghazi S Alotaibi, Abdullah S Al Saleh, Majed Alahmadi, Ibraheem Motabi, Fahad Z Alsharif, Abdullah Alamer, Omar Abduljalil, Imran Tailor, Mohammed Marei, Ahmed S Barefah, Mansour Aljabry, Saud Alhayli, Binyam Usman, Amr Hanbali, Amal Alabdulwahab, Ihab ElHemaidi, Hatem Mahmoud Alahwal, Enas Mutahar, Ahmad Alsaeed","doi":"10.1016/j.clml.2025.05.005","DOIUrl":"https://doi.org/10.1016/j.clml.2025.05.005","url":null,"abstract":"<p><p>Although the therapeutic options for multiple myeloma have improved survival over time, multiple myeloma tends to relapse and become refractory many times over its course. Unfortunately, the chances of survival of the patients affected diminish with each relapse and consequent line of therapy they receive. The management of multiple myeloma, the therapeutic agents available, and the supportive measures recommended for it have significantly evolved since the Saudi Lymphoma/Myeloma Group published its consensus statement on the management of this disease in 2019. Since updated and clear recommendations adapted to Saudi Arabia are crucial to recognize and appropriately treat different progression patterns in order to counsel patients and healthcare payors, the Saudi Myeloma Working Group has created new recommendations for the management of relapsed and/or refractory multiple myeloma and for the provision of supportive care for clinical specialists in Saudi Arabia to respond to these needs.</p>","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144246759","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical Outcomes for Multiple Myeloma Patients With Prior Exposure to a Combination of a Proteasome Inhibitor and an Immunomodulatory Agent in Alberta, Canada","authors":"Victor H. Jimenez-Zepeda ,&nbsp;Mariet Mathew Stephen ,&nbsp;Henry Chan ,&nbsp;Winson Y. Cheung","doi":"10.1016/j.clml.2025.05.006","DOIUrl":"10.1016/j.clml.2025.05.006","url":null,"abstract":"<div><h3>Background</h3><div>Proteasome inhibitors (PI) and immunomodulatory drugs (IMiDs) are important backbones in early line treatments for patients with multiple myeloma (MM). This study examined real-world treatment patterns, clinical outcomes and healthcare resource utilization (HCRU) of double-class exposed (DCE) patients with MM after prior PI and IMiD-based treatment.</div></div><div><h3>Methods</h3><div>DCE patients were identified using integrated administrative databases in the province of Alberta, Canada. DCE patients who commenced subsequent lines of therapy (LOT) between January 2012 and December 2022 were included.</div></div><div><h3>Results</h3><div>Among 831 DCE patients identified to have initiated subsequent LOT during the study period, median age was 68.0 years. IMiD (61%) was the most commonly used therapeutic class after progressing on double-class exposure, followed by PI (39%) and monoclonal antibodies (26%). Attrition rates after first subsequent LOT, defined as death before receiving the next LOT, was 27%, and attrition from second to third subsequent LOT was 30%. Median time to next treatment or death was 12.1 months (95% confidence interval: 10.3-14.1) and median overall survival was 34.4 months (30.3-40.2) from the start of the next subsequent LOT after double-class exposure. healthcare resource utilization (HCRU) during the first year of starting subsequent LOT was high, with a median of 1 ED visit, 1 inpatient admission, 30 clinic visits, 3 infusion appointments, 56 unique healthcare encounters. On average, patients spent 42.2 days on laboratory tests.</div></div><div><h3>Conclusion</h3><div>Clinical outcomes among patients with MM initiating postdouble-class exposure treatments remain suboptimal, with high attrition rates and significant healthcare use, highlighting the need for therapies that reduce patient burden.</div></div>","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":"25 8","pages":"Pages e604-e611.e1"},"PeriodicalIF":2.7,"publicationDate":"2025-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144224556","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Blinatumomab Versus Chemotherapy for Post-Induction Consolidation in First Relapse of B-Cell Acute Lymphoblastic Leukemia: A Systematic Review and Meta-Analysis of Randomized Clinical Trials.","authors":"Anderson Matheus Pereira da Silva, Luciano Falcão Carneiro Filho, Mariana Lee Han, Isabelle Rodrigues Menezes, Elizabeth Honorato de Farias, Marianna Leite, Maria da Vitória Santos do Nascimento, Eryvelton de Souza Franco, Maria Bernadete de Sousa Maia","doi":"10.1016/j.clml.2025.05.004","DOIUrl":"https://doi.org/10.1016/j.clml.2025.05.004","url":null,"abstract":"<p><strong>Background: </strong>Relapsed B-cell acute lymphoblastic leukemia (B-ALL) remains a therapeutic challenge, particularly in children, adolescents, and young adults. Blinatumomab, a bispecific T-cell engager targeting CD19-positive leukemic cells, has emerged as an alternative to conventional chemotherapy in post-induction consolidation. This meta-analysis aimed to evaluate its impact on survival outcomes, relapse rates, and treatment-related toxicities.</p><p><strong>Methods: </strong>A systematic review and meta-analysis were conducted following PRISMA guidelines. Randomized controlled trials (RCTs) comparing blinatumomab to chemotherapy as post-induction consolidation therapy in children, adolescents, and young adults with first relapse of standard-risk B-ALL were included. Primary outcomes were disease-free survival (DFS) and overall survival (OS). Secondary outcomes included cumulative incidence of relapse, measurable residual disease (MRD) negativity, hematopoietic stem cell transplantation (HSCT) eligibility, and treatment-related toxicities. Effect sizes were estimated using hazard ratios (HR) and risk ratios (RR) with 95% confidence intervals (CI).</p><p><strong>Results: </strong>Four RCTs including 703 patients were analyzed. Blinatumomab was associated with improved disease-free survival (DFS) (HR 0.59; 95% CI, 0.42-0.81) and OS (HR 0.57; 95% CI, 0.43-0.76), as well as a lower cumulative incidence of relapse (HR 0.26; 95% CI, 0.16-0.41). Referral for HSCT was more frequent in the blinatumomab group (RR 1.43; 95% CI, 1.10-1.85). Furthermore, blinatumomab was associated with a higher rate of measurable residual disease (MRD) negativity at the end of the first consolidation cycle (RR 1.96; 95% CI, 1.40-2.76).</p><p><strong>Conclusion: </strong>Blinatumomab improved survival outcomes and increased the proportion of patients referred for HSCT, supporting its role as post-induction consolidation therapy for relapsed B-ALL in paediatric and young adult populations.</p>","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144172676","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-World Use of carfilzomib-lenalidomide-dexamethasone (KRd) and carfilzomib-dexamethasone (Kd) in Relapsed/Refractory Multiple Myeloma in the Asia Pacific Region: A Prospective Multicenter Observational Study.","authors":"Hang Quach, Kihyun Kim, Raymond Siu Ming Wong, Si Yun Melinda Tan, Ming-Chung Wang, Kopei Chang, Megan Braunlin, Mihaela Talpes, Rani Najdi, Jin Seok Kim","doi":"10.1016/j.clml.2025.05.001","DOIUrl":"https://doi.org/10.1016/j.clml.2025.05.001","url":null,"abstract":"<p><strong>Background: </strong>Carfilzomib has demonstrated enhanced efficacy and tolerability in head-to-head clinical trials in patients with relapsed/refractory multiple myeloma (RRMM). However, real-world data on its use and outcomes in the Asia Pacific region remains limited.</p><p><strong>Methods: </strong>This prospective, observational, real-world study included 300 RRMM patients from 29 sites in the Asia Pacific region, who received carfilzomib between July 2019 and June 2023. Data was collected from medical records every 3 months to assess safety and efficacy of two approved regimens: carfilzomib with lenalidomide and dexamethasone (KRd) and carfilzomib with dexamethasone alone (Kd).</p><p><strong>Results: </strong>In KRd cohort, mean age was 62.7 years and median prior lines of therapy (LOT) was 1; in Kd cohort, mean age was 66.3 years with a median LOT of 3 (38% ≥ 4 LOTs). KRd achieved an overall response rate (ORR) of 81.7%, including 53.6% complete responses (CR) and 73.3% very good partial responses (VGPR). In the Kd cohort, ORR was 54.5%, with 27.2% CR and 34.8% VGPR. Median overall survival (OS) was 60.9 months with KRd and 41.6 with Kd; median time to progression (TTP) was 38.5 and 23.7 months, respectively. Grade ≥ 3 adverse events occurred in 18.8% (KRd) and 30.7% (Kd); treatment-related events occurred in 4.0% and 8.8%, leading to discontinuations in 1.1% and 2.6%, respectively.</p><p><strong>Conclusion: </strong>Carfilzomib administered as either KRd or Kd was effective and well tolerated, even in patients with multiple prior LOTs, confirming the safety and response rates observed from clinical trials and real-world studies.</p>","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144186705","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Racial and Socioeconomic Disparities in Cutaneous T-Cell Lymphoma Survival: Insights From the National Cancer Database.","authors":"Pamela Allen, Yuan Li, Muhammad Hamid, Jessi Zhi","doi":"10.1016/j.clml.2025.05.002","DOIUrl":"https://doi.org/10.1016/j.clml.2025.05.002","url":null,"abstract":"<p><strong>Objective: </strong>To analyze the impacts of treatment related factors, race, and social determinants of health (SDOH) on patients with cutaneous T-cell lymphoma (CTCL) using a hospital-based registry system.</p><p><strong>Methods: </strong>Patients with CTCL diagnosed from 2004 to 2019 were identified from the National Cancer Database (NCDB). Kaplan-Meier analysis, Cox proportional hazards regression models, and Propensity Score Matching (PSM) were conducted to compare the overall survival between white and Black patients.</p><p><strong>Results: </strong>The NCDB cohort (n = 16,189) included 12,266 (75.8%) white patients, 2849 (17.6%) Black patients, and 1074 (6.6%) other races. There were differences in disease, treatment characteristics and SDOH by racial group. Black patients traveled shorter distances (20.3% vs. 28.9%, P < .001) for treatment and were more likely to reside in urban centers. Rurality (HR 1.74 (1.41-2.15)) and treatment at non-academic/research programs (HR 1.21 (95% CI, 1.11-1.31) were associated with increased risks of death. PSM controlling for demographic, disease, SDOH, and treatment-related variables, demonstrated increased risk of death among Black patients (HR:1.20 (95% CI, 1.10-1.30) P < .001).</p><p><strong>Limitations: </strong>Lack of detailed treatment data and misclassified cases may limit the validity of the study.</p><p><strong>Conclusion: </strong>Black patients have a 20% increased risk of death despite controlling for patient, disease, treatment, and social factors.</p>","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144233378","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}